Table 1 Characteristics of RS₃PE patients with or without malignancy

Age (years)

73.39±9.18

75.00±11.07

73.50±8.51

0.667

Age of onset (years)

73.24±9.23

74.5±11.30

73.4±8.53

0.754

Gender (M/F)

28/23

5/3

21/19

0.710

Pitting edema of hands (n, %)

45 (88.2)

7 (87.5)

35 (87.5)

1

Bilateral (n, %)

42 (93.3)

5 (71.4)

34 (97.1)

0.067

Weight loss (n, %)

18 (35.3)

5 (62.5)

12 (30)

0.112

CEA > 4.7 ng/mL

0^a

/

/

/

AFP > 7ng/mL

1 (2.6)^a

1 (14.3)^c

0^b

0.152

CA19-9 > 39U/mL

2 (5.1)^a

0^c

2 (5.1)^b

1

CYFRA21-1 >3.3 ng/mL

3 (6.5)^a

1 (14.3)^c

2 (5.1)^b

0.398

NSE >16.3 ng/mL

8 (17.4)^a

2 (28.6)^c

6 (18.2)^b

0.587

C reactive protein (mg/L)

43.9 (22.8, 82.0)

35.9 (12.0, 91.0)

45.7 (26.4, 84.9)

0.674

Erythrocyte sedimentation rate (mm/h)

55.37±34.12

48.88±29.00

56.85±35.81

0.558

Immunoglobulin A (g/L)

3.05 (1.62, 3.73)

2.71 (1.18, 3.66)

3.13 (1.62, 4.04)

0.734

Immunoglobulin G (g/L)

12.42±4.74

12.56±5.24

12.32±4.81

0.900

Immunoglobulin M (g/L)

0.71 (0.50, 1.09)

0.68 (0.50, 1.39)

0.71 (0.47, 1.12)

0.968

Complement 3 (g/L)

1.04 (0.87, 1.28)

1.03 (0.79, 1.16)

1.05 (0.88, 1.29)

0.422

Complement 4 (g/L)

0.23±0.09

0.25±0.04

0.24±0/09

0.722

ANA≥1:80 (n, %)

6 (11.8)

0

6 (15)

0.571

Anti-Ro-52 (n, %)

5 (9.8)

1 (12.5)

4 (10)

1

Initial prednisolone dose

15 (15, 30)

15 (10, 30)

15 (15, 27.5)

0.946

Fast response to prednisolone (n, %)

44 (89.8)

3 (42.8)^d

38 (97.4)

0.001^*